Aadi Bioscience (FRA:3350) Dividend Payout Ratio : 0.00 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Aadi Bioscience Dividend Payout Ratio?

Aadi Bioscience's dividend payout ratio for the months ended in Mar. 2024 was 0.00.

The historical rank and industry rank for Aadi Bioscience's Dividend Payout Ratio or its related term are showing as below:

FRA:3350's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.435
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-06-01), the Dividend Yield % of Aadi Bioscience is 0.00%.

Aadi Bioscience's Dividends per Share for the months ended in Mar. 2024 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Aadi Bioscience Dividend Payout Ratio Historical Data

The historical data trend for Aadi Bioscience's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aadi Bioscience Dividend Payout Ratio Chart

Aadi Bioscience Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Aadi Bioscience Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Dividend Payout Ratio	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of Aadi Bioscience's Dividend Payout Ratio

For the Biotechnology subindustry, Aadi Bioscience's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aadi Bioscience's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aadi Bioscience's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Aadi Bioscience's Dividend Payout Ratio falls into.

Aadi Bioscience Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Aadi Bioscience's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0	/	-2.237
	=	N/A

Aadi Bioscience's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	-0.626
	=	N/A

Aadi Bioscience (FRA:3350) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Aadi Bioscience Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Aadi Bioscience's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Aadi Bioscience (FRA:3350) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aadi Bioscience Inc (FRA:3350) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

AADI:USA 3350:Germany

Address

17383 Sunset Boulevard, Suite A250, Pacific Palisades, CA, USA, 90272

Website

https://www.aadibio.com

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

Aadi Bioscience (FRA:3350) Headlines

No Headlines